| 1) ic stability and risking the induction of cancer. |
| 2) of ovarian, head and neck and testicular cancer. |
| 3) role in carcinogenesis, such as in breast cancer. |
| 4) ne loss/osteoporosis in women with breast cancer. |
| 5) ost women undergoing treatment for breast cancer. |
| 6) regimen in patients with advanced breast cancer. |
| 7) of patients undergoing surgery for breast cancer. |
| 8) ntion of scientists to find a solution to cancer. |
| 9) en abnormal differentiation processes and cancer. |
| 10) h after esophagectomy to treat esophageal cancer. |
| 11) phography (CT-LG) in patients with breast cancer. |
| 12) ising vehicle for chemoprevention of skin cancer. |
| 13) r, and proband's son and daughter without cancer. |
| 14) ty and increase susceptibility to bladder cancer. |
| 15) ors over-expressed in non-small cell lung cancer. |
| 16) = 0.036, respectively) compared to breast cancer. |
| 17) erimental animal models and patients with cancer. |
| 18) cer, hepatocellular carcinoma and ovarian cancer. |
| 19) osition and the development of colorectal cancer. |
| 20) drug resistance in aggressive endometrial cancer. |
| 21) nflammatory bowel diseases and colorectal cancer. |
| 22) logical and clinical implications in lung cancer. |
| 23) moresistance and poor prognosis in breast cancer. |
| 24) protocols used for companion animals with cancer. |
| 25) e in the modulation and/or progression of cancer. |
| 26) nd believed they were at low risk of skin cancer. |
| 27) rbs' influence on ovarian and endometrial cancer. |
| 28) mise as novel anticancer agents in canine cancer. |
| 29) A1 haplotypes in the modulation of breast cancer. |
| 30) ew markers of epigenetic dysregulation in cancer. |
| 31) erapeutic or preventive agent for bladder cancer. |
| 32) had good knowledge of the dangers of skin cancer. |
| 33) tion contributes to disease, particularly cancer. |
| |